Amir Mohamed Abdelhamid

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6525508/amir-mohamed-abdelhamid-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

8 papers 239 dest. citations 4 h-index 6 g-index 2.53 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
8	AKT-AMPKEmTOR-dependent HIF-1D ctivation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma Frontiers in Pharmacology, 2021, 12, 720173	5.6	O
7	Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 145, 112455	7.5	2
6	Benzo[a]pyrene immunogenetics and immune archetype reprogramming of lung. <i>Toxicology</i> , 2021 , 463, 152994	4.4	5
5	Blunting p38 MAPKland ERK1/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-B inactivation in mice intoxicated with carbon tetrachloride. <i>Life Sciences</i> , 2021 , 286, 120070	6.8	3
4	Interference With the AMPK/mTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effectively Protects Against the Dextran Sulfate Sodium Intoxication in Rats: A New Paradigm in Empagliflozin and Metforms Reprofiling for the Management of Ulcerative Colitis. Frontiers in Pharmacology, 2021,	5.6	8
3	Telmisartan alleviates alcohol-induced liver injury by activation of PPAR-ANrf-2 crosstalk in mice. <i>International Immunopharmacology</i> , 2021 , 99, 107963	5.8	5
2	Empagliflozin ameliorates ethanol-induced liver injury by modulating NF- B /Nrf-2/PPAR-linterplay in mice. <i>Life Sciences</i> , 2020 , 256, 117908	6.8	11
1	Vildagliptin/pioglitazone combination improved the overall glycemic control in type I diabetic rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018 , 96, 710-718	2.4	4